Status: Not yet recruiting
Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases
Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic disorders in reducing severe aGVHD.
Participants needed: 39
Trial details
Phase: Phase 2Biological sex: AllType: InterventionalSponsor: Anhui Provincial HospitalUpdated: Jun 28, 2024Locations: 1
Eligibility criteria
Malignant hematologic disorders; [+2]
Non-malignant hematologic disorders; [+7]